Methods for production of msc-derived exosomes
AssigneeBoard of Regents, The University of Texas System
InventorsElizabeth SHPALL, Raghu KALLURI, Katy REZVANI, Mayela MENDT, Valerie LEBLEU, Sushrut KAMERKAR
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of manufacturing clinical grade exosomes derived from mesenchymal stem cells (MSCs). Further provided are methods of loading the exosomes with therapeutic agents, such as siRNA. Also provided herein are methods of treating diseases by administering the clinical grade exosome.
Claims22
A method for treating cancer comprising administering an effective amount of the exosomes produced according to the following:
- (a) culturing the MSCs in a functionally closed bioreactor to 75-95% confluency in media comprising human platelet lysate (PLT);
- (b) further culturing the cells in media essentially free of PLT;
- (c) collecting conditioned media fractions from the bioreactor;
- and
- (d) isolating exosomes from the conditioned media fractions.
A method of delivering an RNA into a cell comprising administering an effective amount of RNA-loaded exosomes produced by the following method:
- (a) culturing the MSCs in a functionally closed bioreactor to 75-95% confluency in media comprising human platelet lysate (PLT);
- (b) further culturing the cells in media essentially free of PLT;
- (c) collecting conditioned media fractions from the bioreactor;
- and
- (d) isolating exosomes from the conditioned media fractions.
A method of treating a disease or disorder in subject in need thereof comprising administering an effective amount of exosomes produced by the following method:
- (a) culturing the MSCs in a functionally closed bioreactor to 75-95% confluency in media comprising human platelet lysate (PLT);
- (b) further culturing the cells in media essentially free of PLT;
- (c) collecting conditioned media fractions from the bioreactor;
- and
- (d) isolating exosomes from the conditioned media fractions.
A method of treating an immune-mediated inflammatory disease in a subject suffering from said disease, which comprises administering to said subject a therapeutically effective amount of the MSC-derived exosomes produced according to the following method:
- (a) culturing the MSCs in a functionally closed bioreactor to 75-95% confluency in media comprising human platelet lysate (PLT);
- (b) further culturing the cells in media essentially free of PLT;
- (c) collecting conditioned media fractions from the bioreactor;
- and
- (d) isolating exosomes from the conditioned media fractions.
Dependencies are inferred from the claim text.